Lucera Launches to Revolutionize Drug Development with Decision Intelligence

Lucera GmbH, a newly formed TechBio company based in Heidelberg, Germany, has announced its launch, following the acquisition of Molecular Health's pharmaceutical technology business. With a focus on enhancing decision-making in biopharmaceutical research and development, Lucera aims to make drug development more predictable, evidence-grounded, and efficient.

The core of Lucera's offering is its proprietary technology, Dataome®, which integrates AI with biomedical data to provide decision-ready insights. This platform helps in understanding therapy development, optimizing clinical trials, and predicting side effects. With experienced leadership and a dedicated team from Molecular Health, Lucera targets better-informed decisions, ultimately speeding up product delivery to patients and lowering R&D costs.

Lucera serves a global client base, including biotech firms and investors, aiming to improve program prioritization and resource allocation by providing a deeper understanding of drug candidates.